Equity Overview
Price & Market Data
Price: $10.13
Daily Change: +$0.02 / 0.20%
Daily Range: $10.10 - $10.14
Market Cap: $447,454,272
Daily Volume: 1,192,280
Performance Metrics
1 Week: -0.10%
1 Month: -0.98%
3 Months: 57.30%
6 Months: 29.54%
1 Year: -35.76%
YTD: 31.90%
Company Details
Employees: 173
Sector: Health technology
Industry: Biotechnology
Country:
Details
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.